ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1442

Incident Vascular Events in Danish Nationwide Cohort of Patients with Newly Diagnosed Systemic Lupus Erythematosus
Abstract Number: 0618

Incident versus Prevalent Interstitial Lung Disease in Systemic Sclerosis in the EUSTAR Database: Different Disease Phenotypes and Prognosis
Abstract Number: 1175

Inclusion of All Myositis Specific Autoantibodies or Other Rashes Leads to Better Sensitivity but Lower Specificity of 2017 EULAR/ACR Myositis Classification Criteria for Dermatomyositis
Abstract Number: 1000

Incorporation of Social Drivers of Health Screening into a Structured Healthcare Transition Program for Adolescents and Young Adults with Chronic Rheumatic Disease
Abstract Number: 2363

Increase in Macrophage Infiltration in Scleroderma Esophageal Mucosa Is Associated with Motility and Mucosal Complications
Abstract Number: 1072

Increase in Major Osteoporotic Fractures After Therapy with Immune Checkpoint Inhibitors
Abstract Number: 1086

Increase Shingrix Vaccination Rate in Patients on JAK Inhibitors: A Quality Improvement Project at the Rheumatology Practice of an Urban Institution
Abstract Number: 2206

Increased Frequency of Activated MAIT Cells Expressing the Gut Homing Receptor CCR9 in Patients with Radiographic Axial Spondyloarthritis
Abstract Number: 0972

Increased Incidence of Inflammatory Arthritis After COVID-19 in a Colombian Population
Abstract Number: 1447

Increased Left Ventricular Mass Index in Systemic Lupus Erythematosus Patients with Lupus Nephritis Compared to Those Without Nephritis
Abstract Number: 1703

Increased Mortality and Cardiovascular Events in Male Patients with Systemic Sclerosis: Left Ventricular Global Longitudinal Strain as Possible Screening Tool
Abstract Number: 0181

Increased Prevalence of and Acute Hospital Events Among Medicare Systemic Lupus Erythematosus Patients Living in Socially Vulnerable Counties in the United States
Abstract Number: 0668

Increased Risk of Cancer in Patients with Systemic Sclerosis: A Population-based Study
Abstract Number: 2178

Increased Risk of Dementia in Patients with Primary Sjogren’s Syndrome: A Nationwide Population-based Cohort Study
Abstract Number: 1544

Increased Risk of Severe Infection in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitides: A Population-based Trend Analysis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].